Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study)

AIDS

Volumn 16, Issue 10, 2002, Pages 1331-1340

  Pellegrin, Isabelle ^a,c   Breilh, Dominique ^a   Montestruc, Francois ^a,b   Caumont, Anne ^a   Garrigue, Isabelle ^a   Morlat, Philippe ^a   Le Camus, Cécile ^a,b   Saux, Marie Claude ^a   Fleury, Hervé J A ^a   Pellegrin, Jean Luc ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Roche Pharma   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

Genotype; Nelfinavir; Pharmacokinetic parameters; Protease; Reverse transcriptase

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MULTIVARIATE ANALYSIS; MUTATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMPARATIVE STUDY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMAN; MALE; MULTIVARIATE ANALYSIS; MUTATION; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0037024752     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207050-00004     Document Type: Article

References (36)

1. The effect of high dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients
2. Plasma concentrations of saquinavir (SQV) determine HIV-RNA response over a 48-week period
3. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
4. The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma
5. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial
6. Sequencing of protease inhibitor therapy: Insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors
7. Antiretroviral drug resistance testing in adult HIV infection. Recommendations of an International AIDS Society-USA Panel
8. Multiple concurrent reverse transcriptase and protease mutations and multi-drug resistance of HIV-1 isolates from heavily treated patients
9. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
10. Clinical utility of testing HIV for drug resistance
11. Antiretroviral therapy in patients with suboptimal virologic suppression
12. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
13. Introduction of drug resistance testing in clinical practice
14. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy
15. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotype drug susceptibility with virologic outcome
16. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
17. Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen
18. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
19. Genotypic and phenotypic characterisation of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
20. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
21. Replicative fitness of protease inhibitor-resistant mutants of HIV-1
22. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
23. Correlation between HIV genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
24. Comparison of capillary electrophoresis sequencing with the new CEQ32000 System (Beckman Coulter Inc) to conventional gel based systems for HIV-1 drug resistance analysis
25. Population pharmacokinetics of nelfinavir in 156 HIV infected patients
26. Validation and use of population pharmacokinetic estimates of nelfinavir
27. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial
28. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens
29. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
30. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
31. PharmAdapt: A prospective multicenter randomized controlled trial to evaluate the usefulness of protease inhibitor drug monitoring: 12 Weeks results
32. Therapeutic drug monitoring in the management of subjects on the protease inhibitors nelfinavir and saquinavir: Results of the Roche UK TDM Service
33. Routine therapeutic drug monitoring in patients on protease inhibitors: Impact on therapeutic decisions?
34. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
35. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations